Palisade Bio, Inc.
NASDAQ Capital MarketTotal Valuation
Palisade Bio, Inc. carries a market capitalization of 362.78M, placing it among publicly traded companies globally. Its enterprise value stands at 160.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 362.78M |
| Enterprise Value | 160.71M |
Share Statistics
Palisade Bio, Inc. currently has 167.62M shares outstanding.
| Shares Outstanding | 167.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | -10.44 |
| P/OCF Ratio | -10.44 |
Financial Position
Palisade Bio, Inc. maintains a current ratio of 23.71, meaning it holds 23.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 23.71 |
| Quick Ratio | 23.60 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2,649.20 |
Financial Efficiency
| Return on Equity (ROE) | -36.40 |
| Return on Assets (ROA) | -34.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Palisade Bio, Inc.'s stock has gained approximately 230.33033% over the past 52 weeks. The 50-day moving average sits at 2.02, while the 200-day moving average is 1.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | 230.33033% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.94 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.49M, while operating income came in at -26.49M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -26.49M |
| Pretax Income | -24.15M |
| Net Income | -24.15M |
| EBITDA | -26.49M |
| EBIT | -26.49M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
Total book value stands at 127.36M, with working capital of 127.62M providing operational flexibility.
| Cash & Cash Equivalents | 132.63M |
| Total Debt | N/A |
| Net Debt | -132.63M |
| Equity (Book Value) | 127.36M |
| Book Value Per Share | 0.76 |
| Working Capital | 127.62M |
Cash Flow
Palisade Bio, Inc. produced -12.40M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.40M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.40M |
| FCF Per Share | -0.17 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -46.99 |
| FCF Yield | -9.58 |
Stock Splits
Palisade Bio, Inc.'s most recent stock split took place on April 8, 2024 with a 15:1 split ratio.
| Last Split Date | 4/8/2024 |
| Split Ratio | 15:1 |
Scores
Palisade Bio, Inc. posts an Altman Z-Score of 28.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 28.35 |